Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of HW243040 in Healthy Participants
Sponsor: Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.
Summary
This is a randomised, double-blind, placebo-controlled clinical trial intended to evaluate the safety, tolerability and pharmacokinetic profiles of HW243040 following single and multiple administrations in healthy study participants.
Official title: A Phase 1, Randomized, Double-Blind, Single-Center, Dose-Escalation, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HW243040 in Healthy Participants
Key Details
Gender
All
Age Range
18 Years - 55 Years
Study Type
INTERVENTIONAL
Enrollment
98
Start Date
2026-08-20
Completion Date
2027-05-31
Last Updated
2026-08-27
Healthy Volunteers
Yes
Conditions
Interventions
HW243040
HW243040 will be administered orally as a tablet.
Placebo
Placebo will be administered orally as a tablet.
Locations (1)
The Third Xiangya Hospital of Central South University
Changsha, Hunan, China